Table 2.

Changes in subjective symptoms between the two groups of patients who completed the study.

	SP group	p (intra- group)	LP group	p (intra-group)	p (inter-group)
	Mean ± SD		Mean ± SD
N	57		48
Prostate volume (ml)
baseline	31.7 ± 4.3		64.2 ± 18.9		<0.001
3 months	32.7±9.8	0.46	65.9 ± 19.7	0.93	<0.001
24 months	34.2 ± 9.4	0.07	66.2 ± 19.9	0.86	<0.001
IPSS
baseline	17.9 ± 5.9		19.2 ± 7.1		0.31
3 months	11.0 ± 6.1	<0.001	13.0 ± 6.4	<0.001	0.10
Mean improvement rate from baseline	40.4 %		32.7 %		0.11
24 months	9.7 ± 6.5	<0.001	14.5 ± 7.5	0.002	<0.001
Mean improvement rate from baseline	44.3 %		22.6 %		0.002
IPSS-storage
baseline	7.7 ± 3.0		8.3 ± 2.6		0.22
3 months	5.3 ± 3.1	<0.001	5.7 ± 2.5	<0.001	0.37
Mean improvement rate from baseline	32.5 %		31.0 %		0.79
24 months	4.1 ± 2.8	<0.001	5.8 ± 3.1	<0.001	0.005
Mean improvement rate from baseline	44.0 %		31.0 %		0.05
IPSS-voiding
baseline	10.2 ± 4.5		10.9 ± 5.1		0.43
3 months	5.7 ± 4.1	<0.001	7.3 ± 4.6	<0.001	0.06
Mean improvement rate from baseline	47.9 %		35.0 %		0.03
24 months	5.6±4.3	<0.001	8.7 ± 4.6	0.02	<0.001
Mean improvement rate from baseline	39.6 %		12.5 %		0.006
IPSS-QOL
baseline	4.8 ± 1.0		4.7 ± 0.8		0.89
3 months	3.1 ± 1.3	<0.001	3.1 ± 1.0	<0.001	0.91
Mean improvement rate from baseline	35.2 %		33.4 %		0.66
24 months	2.9 ± 1.1	<0.001	3.7 ± 1.3*	<0.001	<0.001
Mean improvement rate from baseline	39.6 %		20.6 %		<0.001
OABSS
baseline	5.7 ± 3.0		7.0 ± 2.6		0.09
3 months	4.0 ± 2.5	0.008	4.7 ± 2.0	<0.001	0.24
Mean improvement rate from baseline	26.3 %		31.4 %		0.48
24 months	3.7 ± 2.3	<0.001	4.7 ± 2.2	<0.001	0.02
Mean improvement rate from baseline	38.2%		29.6 %		0.32

p (intra-group): versus baseline *: p < 0.05 versus 3 months.

IPSS, International Prostate Symptom Score; LP, large prostate; OABSS, overactive bladder symptom scores; QOL, quality of life; SD, standard deviation; SP, small prostate.